AU2012228236B2 - Diagnostic antibody assay - Google Patents

Diagnostic antibody assay Download PDF

Info

Publication number
AU2012228236B2
AU2012228236B2 AU2012228236A AU2012228236A AU2012228236B2 AU 2012228236 B2 AU2012228236 B2 AU 2012228236B2 AU 2012228236 A AU2012228236 A AU 2012228236A AU 2012228236 A AU2012228236 A AU 2012228236A AU 2012228236 B2 AU2012228236 B2 AU 2012228236B2
Authority
AU
Australia
Prior art keywords
antibody
disease
cells
alzheimer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012228236A
Other languages
English (en)
Other versions
AU2012228236A1 (en
Inventor
Hans-Ulrich Demuth
Kristin EBERMANN
Martin Kleinschmidt
Jens-Ulrich Rahfeld
Stephan Schilling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivoryon Therapeutics NV
Original Assignee
Vivoryon Therapeutics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivoryon Therapeutics NV filed Critical Vivoryon Therapeutics NV
Publication of AU2012228236A1 publication Critical patent/AU2012228236A1/en
Application granted granted Critical
Publication of AU2012228236B2 publication Critical patent/AU2012228236B2/en
Assigned to VIVORYON THERAPEUTICS AG reassignment VIVORYON THERAPEUTICS AG Request to Amend Deed and Register Assignors: PROBIODRUG AG
Assigned to VIVORYON THERAPEUTICS N.V. reassignment VIVORYON THERAPEUTICS N.V. Request to Amend Deed and Register Assignors: VIVORYON THERAPEUTICS AG
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
AU2012228236A 2011-03-16 2012-03-16 Diagnostic antibody assay Ceased AU2012228236B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453449P 2011-03-16 2011-03-16
US61/453,449 2011-03-16
PCT/EP2012/054629 WO2012123562A1 (en) 2011-03-16 2012-03-16 Diagnostic antibody assay

Publications (2)

Publication Number Publication Date
AU2012228236A1 AU2012228236A1 (en) 2013-10-03
AU2012228236B2 true AU2012228236B2 (en) 2016-10-27

Family

ID=45833428

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012228236A Ceased AU2012228236B2 (en) 2011-03-16 2012-03-16 Diagnostic antibody assay

Country Status (15)

Country Link
US (2) US8809508B2 (https=)
EP (1) EP2686346B1 (https=)
JP (1) JP6220675B2 (https=)
KR (1) KR102020072B1 (https=)
CN (1) CN103459421B (https=)
AU (1) AU2012228236B2 (https=)
BR (1) BR112013023211B1 (https=)
CA (1) CA2828433C (https=)
DK (1) DK2686346T3 (https=)
EA (1) EA032054B1 (https=)
IL (1) IL227847A0 (https=)
MX (1) MX343873B (https=)
SG (1) SG192805A1 (https=)
WO (1) WO2012123562A1 (https=)
ZA (1) ZA201305946B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512115B2 (en) 2013-03-15 2016-12-06 Probiodrug Ag Inhibitors
WO2016097305A1 (en) 2014-12-19 2016-06-23 Probiodrug Ag Novel method for the detection of pglu-abeta peptides
US10494425B2 (en) * 2015-02-24 2019-12-03 Rpeptide, Llc Anti-amyloid-beta antibodies
IL256579B2 (en) * 2015-07-16 2023-03-01 Probiodrug Ag Human antibodies
GB201910697D0 (en) * 2019-07-26 2019-09-11 Binding Site Group Ltd Lonisation control
US20210096128A1 (en) * 2019-10-01 2021-04-01 Repligen Corporation Determination of protein concentration in a fluid
KR102790945B1 (ko) * 2022-09-23 2025-04-04 경성대학교 산학협력단 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트
CN121253823A (zh) * 2025-10-10 2026-01-02 山东九嘉生物科技有限公司 一种用于检测胃蛋白酶原ⅰ的化学发光试剂盒及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
ES2275570T3 (es) * 1999-12-08 2007-06-16 Intellect Neurosciences, Inc. Peptidos amiloides beta quimericos.
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
US20100028351A1 (en) 2006-06-29 2010-02-04 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
JP5599614B2 (ja) 2006-11-09 2014-10-01 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
EP2091945B1 (en) 2006-11-09 2014-01-15 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US7803810B2 (en) 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
WO2008128983A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Cyano-guanidine derivatives as glutaminyl cyclase inhibitors
WO2008128982A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
JP5675340B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー 新規阻害剤
JP5675343B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としての尿素誘導体
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP5676249B2 (ja) 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
EP2211886A4 (en) * 2007-10-15 2011-07-27 Centocor Ortho Biotech Inc HUMAN ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, PROCESSES AND APPLICATIONS
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
EP2320942B1 (en) * 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment
PT2448968T (pt) * 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Saido, T.C. et al. Neuroscience Letters. 1996. Vol. 215, No. 3, pages 174-176. *

Also Published As

Publication number Publication date
EP2686346B1 (en) 2016-12-14
BR112013023211B1 (pt) 2022-11-08
NZ614217A (en) 2015-12-24
AU2012228236A1 (en) 2013-10-03
IL227847A0 (en) 2013-09-30
WO2012123562A1 (en) 2012-09-20
JP6220675B2 (ja) 2017-11-01
SG192805A1 (en) 2013-09-30
US9657089B2 (en) 2017-05-23
KR102020072B1 (ko) 2019-11-04
US20140255414A1 (en) 2014-09-11
CN103459421B (zh) 2017-07-14
MX2013010571A (es) 2013-12-02
US8809508B2 (en) 2014-08-19
EA032054B1 (ru) 2019-04-30
KR20140006019A (ko) 2014-01-15
MX343873B (es) 2016-11-25
CN103459421A (zh) 2013-12-18
US20120237529A1 (en) 2012-09-20
BR112013023211A2 (pt) 2016-11-22
CA2828433A1 (en) 2012-09-20
JP2014509860A (ja) 2014-04-24
EA201301029A1 (ru) 2014-05-30
DK2686346T3 (en) 2017-03-27
CA2828433C (en) 2020-08-04
EP2686346A1 (en) 2014-01-22
ZA201305946B (en) 2014-10-29

Similar Documents

Publication Publication Date Title
CN102131519B (zh) 诊断抗体测定
US9657089B2 (en) Diagnostic antibody assay
HK1192568A (en) Diagnostic antibody assay
HK1192568B (en) Diagnostic antibody assay
NZ614217B2 (en) Diagnostic antibody assay
HK1158946B (en) Diagnostic antibody assay

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: VIVORYON THERAPEUTICS AG

Free format text: FORMER NAME(S): PROBIODRUG AG

Owner name: VIVORYON THERAPEUTICS N.V.

Free format text: FORMER NAME(S): VIVORYON THERAPEUTICS AG

MK14 Patent ceased section 143(a) (annual fees not paid) or expired